Company / Total Assets
Theravance Biopharma, Inc. Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$485.6M
FY2025
5-year range
$354.2M / $607.4M
FY2021-FY2025
Trend
+37.1%
vs FY2024
Sector context
#144 of 214
Health Care
What the data says
At $486M, Theravance Biopharma, Inc.'s total assets ranks #144 of 214 in the Health Care sector. Total Assets returned to growth in FY2025 after 2 years of decline, reaching $486M.
Based on SEC 10-K filings.
$486M in FY2025 with a 5-year CAGR of +0.7%.
Improved from $382M to $486M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- -7.2%
- 5-Year CAGR
- +0.7%
- 10-Year CAGR
- -
Sector benchmark
#144 of 214 in Health CareTop 67% of 214This company $485.6M Sector average $7.5B
▼
-93.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +0.7%, indicating consistent growth.
- In FY2025, total assets increased 37.1% year-over-year.
- Ranks #144 out of 214 companies in the Health Care sector.
- Peak total assets was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $485.6M | +37.1% |
| FY2024 | $354.2M | -7.3% |
| FY2023 | $382.0M | -37.1% |
| FY2022 | $607.4M | +62.1% |
| FY2021 | $374.8M | -20.1% |
| FY2020 | $469.1M | +14.7% |
| FY2019 | $408.8M | -27.0% |
| FY2018 | $560.2M | +26.9% |
| FY2017 | $441.4M | -31.0% |
| FY2016 | $639.3M | +113.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026